Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 7/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.38 |
| ▸ | TACR1 | P25103 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.34 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.34 |
| ▸ | UBE2N | P61088 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL837439 | 0.89 | HTT (0.35) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL837267 | 0.89 | NR4A2 (0.39) | SLC6A4TACR1KDM4EALDH1A1LMNA | |
| SCHEMBL837920 | 0.88 | MTNR1A (0.45) | TACR1KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL6044676 | 0.85 | KDM4E (0.45) | TACR1KDM4EALDH1A1MAPTL3MBTL1 | |
| SCHEMBL837253 | 0.81 | MPO (0.45) | MPOGPR84SLC6A4KDM4EALDH1A1 | |
| SCHEMBL837467 | 0.76 | SPR (0.30) | — | |
| SCHEMBL4640443 | 0.75 | GPR84 (0.39) | GPR84TACR1ALDH1A1LMNA | |
| SCHEMBL837266 | 0.69 | NR4A2 (0.44) | SLC6A4KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL837438 | 0.69 | ALDH1A1 (0.39) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL836529 | 0.69 | NR4A2 (0.39) | MAPTUBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081214-A2 | INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2384753-B1 | Hydantoin derivatives as inhibitors of cellular necrosis | BRIGHAM & WOMENS HOSPITAL (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8741942-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-03 | — | — | US | disclosed |
| US-20120149702-A1 | INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8143300-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2384753-A1 | Hydantoin derivatives as inhibitors of cellular necrosis | The Brigham and Women's Hospital, Inc. (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20110144169-A1 | Inhibitors of cellular necrosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-16 | — | — | US | disclosed |
| US-7491743-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1663184-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005077344-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050119260-A1 | Inhibitors of cellular necrosis | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119260-A1 | Inhibitors of cellular necrosis | TNF, AIFM1, BAD | MPO 43/4885GPR84 4197/4885SLC6A4 3792/4885 |
| US-20110144169-A1 | Inhibitors of cellular necrosis | TNF, AIFM1, BAD | MPO 43/4885GPR84 4197/4885SLC6A4 3792/4885 |
| US-20120149702-A1 | INHIBITORS OF CELLULAR NECROSIS | TNF, AIFM1, BAD | MPO 43/4885GPR84 4197/4885SLC6A4 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.